Customer Service 1 (888) 261-2693
Advanced Search

Last Chance to Get in on This No-Brainer Biotech Trade

By Dr. George Huang
Friday, April 11, 2008

Back in December, I told you the bleak story of Neurocrine Biosciences (NBIX)...
 
A week earlier, the company had received a crushing blow from the FDA, dished out in a notorious "approvable letter."
 
Approvable letters are the FDA's way of turning a "yes/no" decision on a new drug into a "maybe." In other words, the drug is "approvable," so long as the drug's maker meets certain conditions.
 
In the case of Neurocrine's insomnia drug, Indiplon, the FDA wanted additional animal studies, plus two more clinical trials, which would have cost the company as much as $50 million. To be honest, the new requests were preposterous. But this isn't the first time the FDA has moved back the goalposts on a drugmaker...

Back in May 2006, Neurocrine received its first approvable letter for Indiplon, prompting its Big Pharma partner, Pfizer, to cut ties. The stock dropped from $50 per share down to $20. News of the second approvable letter this past December once again sent shareholders running...
 
 
 
In December, I said the FDA would never approve Indiplon. Still, Neurocrine was not worthless. The company had about $4.50 in cash per share, more than 92% of its market cap. 
 
In addition, Neurocrine had a pipeline full of innovative compounds. Its drug for endometriosis (a disease of the uterus) was in Phase IIb clinical trials. And GlaxoSmithKline was collaborating on drugs for anxiety and irritable bowel syndrome, both in Phase IIa testing.
 
But before I was willing to jump into the stock, two things needed to happen:
 
1. Neurocrine management had to show some resolve, take Indiplon behind the woodshed, and kill it.
 
2. The stock needed to get a bit cheaper to provide investors a larger margin of safety.
 
Both things happened in a hurry...
 
Long-time CEO Gary Lyons resigned in January – less than a month after sending pink slips to half of the company's employees. Chief Operating Officer Kevin Gorman took the post and immediately won me over on his first conference call:
 
"There are no expenditures in our budget for Indiplon going forward..." Indiplon is no longer a threat to the company's coffers.
 
The stock popped up in the news, then traded back down to around $4.50 per share – our fair-value estimate – making Neurocrine a true bargain.
 
One San Francisco-based biotech hedge fund I admire – the Biotech Value Fund – jumped in. The firm scooped up more than 2 million Neurocrine shares during February and March at an average cost of $5 per share.
 
If you bought in February, when Neurocrine qualified as a "no-brainer" trade, you're already up about 15%. And I firmly believe that Neurocrine will trade above $8 per share within the next 12 months, a return of roughly 50% on the year.
 
The Neurocrine story exactly fits the bill for trades I will be featuring in my newsletter, the S&A FDA Report.
 
Based on our eight-year study, buying the best stocks after they've been hit with an FDA setback returns an average of 75% in a year. I'm confident Neurocrine will follow suit.
 
Good trading,
 
George Huang, PhD




Recent Articles
Market Notes
Retail behemoth Wal-Mart raises its forecast, hits a new high...
 
Other retailers fall... American Eagle, Chico's, and Tween Brands hit new lows.
 
Small banks still hurting... Crescent Financial, FNB United, PFF Bancorp, SVB Financial, Cathay General, and Downey Financial hit new lows.
 
Earnings today... General Electric.
Market Watch
Symbol Price
Change
52-Wk
S&P 500 1240.40 +0.6% +12.5%
Oil 37.66 -0.7% +5.4%
Gold 135.41 +0.0% +22.2%
Silver 27.98 -0.2% +63.7%
US-Dollar 80.01 +0.0% +5.3%
Euro 1.32 -0.1% -10.2%
Volatility 17.61 +2.1% -21.1%
Gold Stocks 570.52 +0.4% +25.8%
10-Year Yield 3.30 +2.5% -5.2%

World ETFs
Symbol Price
Change
52-Wk
USA 124.48 +0.6% +12.5%
Canada 30.50 +0.8% +17.9%
Russia 21.90 +0.2% +20.9%
India 37.10 +1.3% +20.1%
Israel 17.00 +1.5% +11.7%
Japan 10.58 -0.3% +7.0%
Singapore 13.76 -0.3% +19.2%
Taiwan 14.98 +0.3% +20.4%
S. Korea 57.95 +0.1% +22.9%
S. Africa 71.90 +0.3% +30.4%
China 43.43 +0.2% -0.2%
Lat.America 52.23 +0.7% +8.0%

Sector ETFs
Symbol Price
Change
52-Wk
Oil Service 136.18 +0.1% +19.1%
Big Pharma 64.58 +0.6% -2.7%
Internet 73.29 +0.6% +28.1%
Semis 16.60 +0.1% +30.0%
Utilities 31.12 +0.4% -0.5%
Defense 18.51 +0.7% +9.4%
Nanotech 10.03 +0.3% +0.6%
Alt. Energy 10.41 +1.2% -1.2%
Water 19.09 +1.6% +16.7%
Insurance 16.41 +0.6% +21.8%
Biotech 20.95 +1.5% +30.1%
Retail 19.67 +0.5% +28.3%
Software 25.21 +0.7% +28.0%
Big Tech 54.49 +0.7% +23.0%
Construction 13.46 +1.1% +19.1%
Media 13.97 +1.2% +22.7%
Consumer Svcs 67.72 +0.4% +23.2%
Financials 56.86 +0.8% +11.3%
Health Care 64.83 +1.1% +2.0%
Industrials 64.47 +1.1% +22.2%
Basic Mat 74.82 +1.0% +28.1%
Real Estate 54.67 +1.0% +23.7%
Transportation 92.29 +0.3% +25.5%
Telecom 23.00 +0.4% +17.1%